GHRP-2 — compound monograph
Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide). Approved. The Institute assesses 2 outcomes for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- GHRP-2
- Compound class
- Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide)
- Assessment series
- Growth-hormone axis
- Synonyms and codes
- pralmorelin · KP-102 · GPA-748 · pralmorelin hydrochloride
- Route as evaluated
- Intravenous for the approved diagnostic use; subcutaneous in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 158861-67-7
- Molecular formula
- C45H55N9O6
- Average mass
- 817.97
- Monoisotopic mass
- 817.42
- ATC classification
- V04CD06
§1.3Sequence and structural notes
A hexapeptide secretagogue. Notably, pralmorelin holds a diagnostic marketing authorisation in Japan for the assessment of growth-hormone secretory reserve — one of very few compounds in the research-peptide category with any approval anywhere.
§1.4Assessment status
The Institute assesses GHRP-2 across 2 indications and grades the strongest of them at low certainty. Holds a marketing authorisation for at least one indication in at least one jurisdiction.
Table 1. Assessed outcomes for GHRP-2, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Growth hormone deficiency and growth-hormone secretagogue pharmacology | A peak growth hormone below 16 ng/mL after 100 µg intravenously supports severe adult growth-hormone deficiency in the approved Japanese diagnostic… | Moderate | 1 |
| Sarcopenia and lean-mass preservation during weight reduction | No randomised human evidence identified for a body-composition outcome | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.